Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21221559 | 0.96 | CYP4A11 (0.57) | CYP4A11CYP4F2CA1CA2MGLL | |
| SCHEMBL1936202 | 0.90 | MGLL (0.55) | CYP4A11CYP4F2CA1CA2MGLL | |
| SCHEMBL2328583 | 0.88 | TDP1 (0.51) | CA1CA2TDP1POLBBRD4 | |
| SCHEMBL22915442 | 0.87 | CA1 (0.57) | CYP4A11CYP4F2CA1CA2MGLL | |
| SCHEMBL1794948 | 0.87 | CA1 (0.49) | CYP4A11CA1CA2MGLLTDP1 | |
| SCHEMBL4465651 | 0.86 | MGLL (0.51) | CYP4A11CYP4F2CA1CA2MGLL | |
| SCHEMBL30905400 | 0.86 | POLB (0.67) | CA1CA2MGLLTDP1POLB | |
| SCHEMBL31307112 | 0.85 | TDP1 (0.54) | CA1CA2TDP1POLBSIGMAR1 | |
| SCHEMBL31307113 | 0.85 | TDP1 (0.58) | CA1CA2TDP1POLBSIGMAR1 | |
| SCHEMBL917871 | 0.85 | TDP1 (0.54) | CA1CA2TDP1POLBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241528-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-10167266-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-8846688-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8198286-B2 | Sodium channel blockers | PARION SCIENCES, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1485360-B1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20090227530-A1 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090062308-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-20070265280-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1485360-A4 | SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | CYFI, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| EP-1485360-A2 | SODIUM CHANNEL BLOCKERS | Johnson, Michael R. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003070182-A2 | SODIUM CHANNEL BLOCKERS | JOHNSON MICHAEL R (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267650-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CYP4A11 1954/4885CYP4F2 4098/4885CA1 873/4885 |
| US-10167266-B2 | Sodium channel blockers | SCNN1B, SCNN1A, SCNN1G | CYP4A11 2080/4885CYP4F2 2670/4885CA1 656/4885 |
| US-20150376146-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CYP4A11 1954/4885CYP4F2 4098/4885CA1 873/4885 |
| US-20070265280-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | SCN1B, KCNN3, SCN2B | CYP4A11 1602/4885CYP4F2 1682/4885CA1 589/4885 |
| US-20060142306-A1 | Bronchodilator agents; respiratory system disorders; skin disorders ; asthma; hypotensive agents | ADRB2, ADRB3, ADRA1D | CYP4A11 1257/4885CYP4F2 3763/4885CA1 3670/4885 |
| US-20140179625-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CYP4A11 1954/4885CYP4F2 4098/4885CA1 873/4885 |
| US-20090227530-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CYP4A11 1954/4885CYP4F2 4098/4885CA1 873/4885 |
| US-20130012692-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CYP4A11 1954/4885CYP4F2 4098/4885CA1 873/4885 |
| US-20090062308-A1 | METHODS OF USING SODIUM CHANNEL BLOCKERS | SCN1B, KCNN3, SCN2B | CYP4A11 1602/4885CYP4F2 1682/4885CA1 589/4885 |
| US-20190241528-A1 | SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCN5A | CYP4A11 1954/4885CYP4F2 4098/4885CA1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.